JP6456394B2 - 胎児仮死の診断 - Google Patents
胎児仮死の診断 Download PDFInfo
- Publication number
- JP6456394B2 JP6456394B2 JP2016543421A JP2016543421A JP6456394B2 JP 6456394 B2 JP6456394 B2 JP 6456394B2 JP 2016543421 A JP2016543421 A JP 2016543421A JP 2016543421 A JP2016543421 A JP 2016543421A JP 6456394 B2 JP6456394 B2 JP 6456394B2
- Authority
- JP
- Japan
- Prior art keywords
- fetal
- uric acid
- sample
- pregnant mother
- eclampsia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000033300 perinatal asphyxia Diseases 0.000 title claims description 30
- 238000003745 diagnosis Methods 0.000 title claims description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 79
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 43
- 229940116269 uric acid Drugs 0.000 claims description 43
- 230000035935 pregnancy Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 201000011461 pre-eclampsia Diseases 0.000 claims description 22
- 210000003296 saliva Anatomy 0.000 claims description 20
- 238000012544 monitoring process Methods 0.000 claims description 16
- 230000008774 maternal effect Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000032943 Fetal Distress Diseases 0.000 claims description 6
- 206010016855 Foetal distress syndrome Diseases 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 206010070538 Gestational hypertension Diseases 0.000 claims description 5
- 208000002296 eclampsia Diseases 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 4
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 4
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 208000030941 fetal growth restriction Diseases 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 4
- 230000035606 childbirth Effects 0.000 claims description 3
- 230000035487 diastolic blood pressure Effects 0.000 claims description 2
- 230000009593 intrauterine fetal growth Effects 0.000 claims description 2
- 230000035488 systolic blood pressure Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010003497 Asphyxia Diseases 0.000 description 3
- 230000006609 metabolic stress Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 206010051133 Meconium in amniotic fluid Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000019547 Placental disease Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000025934 placenta disease Diseases 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 201000005608 severe pre-eclampsia Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316668.1A GB201316668D0 (en) | 2013-09-19 | 2013-09-19 | Diagnosis of foetal distress |
| GB1316668.1 | 2013-09-19 | ||
| PCT/EP2014/070053 WO2015040190A1 (en) | 2013-09-19 | 2014-09-19 | Diagnosis of foetal distress |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531305A JP2016531305A (ja) | 2016-10-06 |
| JP2016531305A5 JP2016531305A5 (enExample) | 2017-09-07 |
| JP6456394B2 true JP6456394B2 (ja) | 2019-01-23 |
Family
ID=49553104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543421A Active JP6456394B2 (ja) | 2013-09-19 | 2014-09-19 | 胎児仮死の診断 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160231306A1 (enExample) |
| EP (1) | EP3047269B1 (enExample) |
| JP (1) | JP6456394B2 (enExample) |
| CA (1) | CA2922894C (enExample) |
| DK (1) | DK3047269T3 (enExample) |
| ES (1) | ES2687971T3 (enExample) |
| GB (1) | GB201316668D0 (enExample) |
| WO (1) | WO2015040190A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3442415B1 (en) | 2016-04-14 | 2025-05-28 | Morgan Innovation & Technology Ltd | Methods for measuring the levels of analytes in body fluids |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313828D0 (en) * | 2003-06-16 | 2003-07-23 | Owen Smith Brian D O | Salivary urate for diagnosis of pre-eclampsia |
-
2013
- 2013-09-19 GB GBGB1316668.1A patent/GB201316668D0/en not_active Ceased
-
2014
- 2014-09-19 CA CA2922894A patent/CA2922894C/en active Active
- 2014-09-19 EP EP14772109.6A patent/EP3047269B1/en active Active
- 2014-09-19 WO PCT/EP2014/070053 patent/WO2015040190A1/en not_active Ceased
- 2014-09-19 US US15/023,002 patent/US20160231306A1/en not_active Abandoned
- 2014-09-19 DK DK14772109.6T patent/DK3047269T3/en active
- 2014-09-19 JP JP2016543421A patent/JP6456394B2/ja active Active
- 2014-09-19 ES ES14772109.6T patent/ES2687971T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2922894A1 (en) | 2015-03-26 |
| EP3047269A1 (en) | 2016-07-27 |
| WO2015040190A1 (en) | 2015-03-26 |
| CA2922894C (en) | 2022-05-03 |
| DK3047269T3 (en) | 2018-09-17 |
| EP3047269B1 (en) | 2018-08-01 |
| US20160231306A1 (en) | 2016-08-11 |
| JP2016531305A (ja) | 2016-10-06 |
| GB201316668D0 (en) | 2013-11-06 |
| ES2687971T3 (es) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7657195B2 (ja) | 収縮期血圧、血液パラメーター、およびこれらの組み合わせを含むバイタルサインを使用して敗血症を検出する方法 | |
| Haws et al. | Reducing stillbirths: screening and monitoring during pregnancy and labour | |
| Visser et al. | FIGO consensus guidelines on intrapartum fetal monitoring: Adjunctive technologies | |
| US20170052193A1 (en) | Fertility and pregnancy monitoring device and method | |
| Lin et al. | The value of serum uric acid in predicting adverse pregnancy outcomes of women with hypertensive disorders of pregnancy | |
| Buhling et al. | The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes | |
| Lauszus et al. | Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation | |
| JP6456394B2 (ja) | 胎児仮死の診断 | |
| Gribbin et al. | Assessing fetal health | |
| Lindberg | Epidemiology of hypertension during pregnancy | |
| Nesrallah et al. | The effect of timing of removal of wound dressing on surgical site infection rate after cesarean delivery [23N] | |
| Shennan et al. | Measuring blood pressure in pregnancy and | |
| KR102482468B1 (ko) | 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스 | |
| Proctor et al. | Does a policy of earlier induction affect labour outcomes in women induced for postmaturity? A retrospective analysis in a tertiary hospital in the North of England | |
| Behrman et al. | Measurement of fetal and infant maturity | |
| Pandala et al. | A comparative study of the glucose challenge test, fasting blood glucose test, and post-prandial blood glucose screening to identify gestational diabetes mellitus | |
| Sheng | Study on Diagnosis of Fetal Chromosomal Abnormalities by Ultrasound Screening and Ultrasound-Guided Amniocentesis | |
| Yusuf et al. | Relationship between abnormal cardiography and cord blood pH at birth in term pregnancies | |
| Bibi et al. | EXPLORING THE ROLE OF ADVANCED DOPPLER ULTRASOUND IMAGING IN EARLY DETECTION OF FETAL COMPLICATIONS IN HYPERTENSIVE PREGNANCIES | |
| RU2521359C2 (ru) | Способ определения степени тяжести гестоза у беременных | |
| Poon et al. | Inter-arm blood pressure differences in pregnant women | |
| Higgins et al. | The Berlin Questionnaire for Assessment of Sleep-disordered Breathing Risk in Parturients and Nonpregnant Women | |
| CN118506981A (zh) | 基于数据分析的产科患者手术风险评估方法及系统 | |
| McKay | A guide to less common antenatal blood tests | |
| Wing et al. | Prenatal Use of Aspirin and Acetaminophen [22N] |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170725 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170725 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180423 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180814 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181023 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6456394 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |